Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday

Prelude Therapeutics (NASDAQ:PRLD) is anticipated to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Prelude Therapeutics to post earnings of ($0.33) per share and revenue of $20.50 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Prelude Therapeutics Price Performance

Shares of NASDAQ:PRLD opened at $2.76 on Monday. The stock has a market cap of $173.52 million, a price-to-earnings ratio of -1.88 and a beta of 0.79. The company has a 50 day moving average of $2.34 and a 200-day moving average of $1.75. Prelude Therapeutics has a one year low of $0.61 and a one year high of $4.22.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On Prelude Therapeutics

Several hedge funds have recently bought and sold shares of PRLD. XTX Topco Ltd boosted its position in shares of Prelude Therapeutics by 222.0% during the fourth quarter. XTX Topco Ltd now owns 50,159 shares of the company’s stock worth $145,000 after purchasing an additional 34,581 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in Prelude Therapeutics during the 4th quarter worth $356,000. OMERS ADMINISTRATION Corp bought a new position in Prelude Therapeutics during the fourth quarter worth about $212,000. Marshall Wace LLP acquired a new position in Prelude Therapeutics in the fourth quarter valued at about $794,000. Finally, State Street Corp increased its holdings in shares of Prelude Therapeutics by 30.4% in the fourth quarter. State Street Corp now owns 127,292 shares of the company’s stock worth $369,000 after acquiring an additional 29,700 shares in the last quarter. 79.72% of the stock is currently owned by institutional investors and hedge funds.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.